WASHINGTON, D.C. -- Today, U.S. Rep. Mike Kelly (R-PA) applauded the Trump administration's announcement Thursday that the administration has reached a deal to lower the cost of popular GLP-1 weight loss drugs, Wegovy and Zepbound.

The announcement follows Kelly's introduction of the Treat and Reduce Obesity Act (TROA), bipartisan legislation to combat the obesity crisis in the United States by providing Medicare coverage of GLP-1s.

"The Trump administration's proactive efforts to work with pharmaceutical companies to lower the cost of these life-saving prescription drugs will help Americans save money and live healthier lives," said Rep. Kelly. "This effort wholly aligns with my bipartisan legislation, the Treat and Reduce Obesity Act, which would require Medicare coverage of GLP-1s. Through this commonsense policy, seniors struggling with obesity will be able to take a responsible, proactive approach to improve their health and live longer, more active lives. It has been a pleasure to work with the Trump administration, including my friend Dr. Oz, to make America healthy again; and, my friend, former Rep. Brad Wenstrup, DPM, together in Congress. There is always more work to be done, and I look forward to continued work in Congress to cover this life-saving medication!"

You can find full bill text for the Treat and Reduce Obesity Act here.